About: SARS‐CoV‐2‐reactive interferon‐γ‐producing CD8+ T cells in patients hospitalized with coronavirus disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS‐CoV‐2‐reactive interferon‐γ‐producing CD8+ T cells in patients hospitalized with coronavirus disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS‐CoV‐2‐reactive interferon‐γ‐producing CD8+ T cells in patients hospitalized with coronavirus disease 2019
Creator	Giménez, Estela Albert, Eliseo María, \| Alcaraz, Jesús Blasco, Luisa Carlos Solano, \| David Navarro, \| Forner, José Galindo, José Redón, Josep Remigia, José Signes-Costa, Jaime Torres, Ignacio
Source	Medline; PMC; WHO
abstract	There is limited information on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) T‐cell immune responses in patients with coronavirus disease 2019 (COVID‐19). Both CD4+ and CD8+ T cells may be instrumental in resolution of and protection from SARS‐CoV‐2 infection. Here, we tested 25 hospitalized patients either with microbiologically documented COVID‐19 (n = 19) or highly suspected of having the disease (n = 6) for presence of SARS‐CoV‐2‐reactive CD69+ expressing interferon‐γ (IFN‐γ) producing CD8+ T cells using flow‐cytometry for intracellular cytokine staining assay. Two sets of overlapping peptides encompassing the SARS‐CoV‐2 Spike glycoprotein N‐terminal 1 to 643 amino acid sequence and the entire sequence of SARS‐CoV‐2 M protein were used simultaneously as antigenic stimulus. Ten patients (40%) had detectable responses, displaying frequencies ranging from 0.15 to 2.7% (median of 0.57 cells/µL; range, 0.43‐9.98 cells/µL). The detection rate of SARS‐CoV‐2‐reactive IFN‐γ CD8+ T cells in patients admitted to intensive care was comparable (P = .28) to the rate in patients hospitalized in other medical wards. No correlation was found between SARS‐CoV‐2‐reactive IFN‐γ CD8+ T‐cell counts and SARS‐CoV‐2 S‐specific antibody levels. Likewise, no correlation was observed between either SARS‐CoV‐2‐reactive IFN‐γ CD8+ T cells or S‐specific immunoglobulin G‐antibody titers and blood cell count or levels of inflammatory biomarkers. In summary, in this descriptive, preliminary study we showed that SARS‐CoV‐2‐reactive IFN‐γ CD8+ T cells can be detected in a non‐negligible percentage of patients with moderate to severe forms of COVID‐19. Further studies are warranted to determine whether quantitation of these T‐cell subsets may provide prognostic information on the clinical course of COVID‐19.
has issue date	2020-07-02(xsd:dateTime)
bibo:doi	10.1002/jmv.26213
bibo:pmid	32579268
has license	no-cc
sha1sum (hex)	df446519c7a1187d036c6f7a4cf95fdfb7511530
schema:url	https://doi.org/10.1002/jmv.26213
resource representing a document's title	SARS‐CoV‐2‐reactive interferon‐γ‐producing CD8+ T cells in patients hospitalized with coronavirus disease 2019
has PubMed Central identifier	PMC7361624
has PubMed identifier	32579268
schema:publication	J Med Virol
resource representing a document's body	covid:df446519c7a1187d036c6f7a4cf95fdfb7511530#body_text
is schema:about of	named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'highly' named entity 'glycoprotein' named entity 'cytokine' named entity 'SARS-CoV-2' named entity 'expressing' named entity 'RT-PCR' named entity 'Fisher exact test' named entity '11 March 2020' named entity 'RBD' named entity 'CD8+ T cells' named entity 'disease' named entity 'interferon-γ' named entity 'assay' named entity 'infection' named entity 'glycoprotein' named entity 'protein' named entity 'amino acid sequence' named entity 'coronavirus disease 2019' named entity 'interferon-γ' named entity 'CD8+ T cells' named entity 'SARS-CoV' named entity 'virus' named entity 'CD8+ T cells' named entity 'acute respiratory distress syndrome' named entity 'peripheral blood mononuclear cells' named entity 'infection' named entity 'immunosenescence' named entity 'IFN-γ' named entity 'interferon-γ' named entity 'antigenic' named entity 'COVID-19' named entity 'Clinical laboratory' named entity 'IFN-γ' named entity 'microbiological' named entity 'SARS-CoV-2' named entity 'CD8+ T cells' named entity 'SARS-CoV-2' named entity '28 days' named entity 'cross-reactive' named entity 'complete blood count' named entity 'assay' named entity 'SARS-CoV-2' named entity 'SARS' named entity 'coronaviruses' named entity 'IFN-γ' named entity 'SARS-CoV-2' named entity 'pneumonia' named entity 'asymptomatic' named entity 'flow cytometry' named entity 'seroconversion' named entity 'cytotoxic T lymphocyte' named entity 'CD8+ T cells' named entity 'Dot-plot' named entity 'immunogenic' named entity 'SARS-CoV-2' named entity 'cytopenias' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'CD8+ T cells' named entity 'SARS-CoV-2' named entity 'HLA' named entity 'infection' named entity 'BD Biosciences' named entity 'CD4+ T cells' named entity 'peptides' named entity 'CD4+' named entity 'T-cell' named entity 'IFN-γ'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software